| Literature DB >> 25187159 |
Xin-wei Yang, Jian-mao Yuan, Jun-yi Chen, Jue Yang, Quan-gen Gao, Xing-zhou Yan, Bao-hua Zhang1, Shen Feng, Meng-chao Wu.
Abstract
BACKGROUND: Preoperative jaundice is frequent in gallbladder cancer (GBC) and indicates advanced disease. Resection is rarely recommended to treat advanced GBC. An aggressive surgical approach for advanced GBC remains lacking because of the association of this disease with serious postoperative complications and poor prognosis. This study aims to re-assess the prognostic value of jaundice for the morbidity, mortality, and survival of GBC patients who underwent surgical resection with curative intent.Entities:
Mesh:
Year: 2014 PMID: 25187159 PMCID: PMC4164789 DOI: 10.1186/1471-2407-14-652
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Figure 1Typical operative field after wedge resection with a 2 cm margin (including segments IVb/V) and skeletonization of the hepatoduodenal ligament. We state that the subject of the photograph has given written informed consent by the patient to publication of the photograph. PV, portal vein; IVC, inferior vena cava; PHA, proper hepatic artery; RHA, right hepatic artery; LHA, left hepatic artery; MHA, middle hepatic artery; GDA, gastroduodenal artery
Figure 2Typical imaging feature of gallbladder carcinoma involving the hepatic hilum. a. Enhanced CT shows gallbladder carcinoma with hepatic invasion. b. Preoperative MRCP shows that gallbladder carcinoma is located in the neck invading the hepatic hilum. The right hepatic artery and the common bile duct were involved by tumor in the surgery. We state that the subject of the photograph has given written informed consent by the patient to publication of the photograph. GB, gallbladder, CHD, common hepatic duct; IVC, inferior vena cava; PV, portal vein; PD, pancreatic duct.
Demographic data of jaundiced (n = 47) and non-jaundiced GBC patients (n = 145)
| Jaundiced, n | Non-jaundiced, n | p-value | |
|---|---|---|---|
| Male gender | 21 | 45 | 0.088 |
| Mean age (range) | 57.5 ± 11.0(35-80) | 58.2 ± 10.2(23-83) | 0.725 |
| Postoperative hospital stay | 19.7 ± 13.3 (4–85) | 11.5 ± 6.4 (5–51) | < 0.001 |
| Associated gallbladder disease | 0.983 | ||
| Gallstones | 26 (55.3%) | 80 (55.2%) | |
| Gallbladder polyp | 1 (2.1%) | 3 (2.0%) | |
| Nil | 20 (42.6%) | 62 (42.8%) | |
| Tumor location | < 0.001 | ||
| Gallbladder neck | 28 (59.6) | 26 (17.9) | |
| Gallbladder body | 10 (21.3) | 70 (48.3) | |
| Gallbladder fundus | 9 (19.1) | 49 (33.8) | |
| Histologic type | 0.259 | ||
| Well differentiated | 2 (4.3) | 9 (6.2) | |
| Moderately differentiated | 41 (87.2) | 109 (75.2) | |
| Poorly differentiated | 4 (8.5) | 27 (18.6) | |
| Extent of liver resection | 0.590 | ||
| Major hepatectomy (>3 segments) | 4 | 4 | |
| Anatomical segments IV-V | 8 | 42 | |
| Gallbladder bed | 35 | 99 | |
| Extrahepatic bile duct resection | 44 (93.6) | 12 (8.3%) | < 0.001 |
| Pathologic extrahepatic bile duct invasion | 38 (80.9) | 12 (8.3%) | < 0.001 |
| Combined resection of adjacent organs | 11 (23.4%) | 4 (2.8%) | < 0.001 |
| Hepatic invasion | 26 (55.3%) | 64 (44.1%) | 0.183 |
| Lymph node metastasis | 30 (63.8%) | 72 (49.7%) | 0.091 |
| Vascular invasion | 2 (4.3) | 3 (2.1%) | 0.415 |
| pT | 0.019 | ||
| pT1-2 | 16 (34.1%) | 78 (53.8%) | |
| pT3-4 | 31 (65.9%) | 67 (46.2%) | |
| Intra-operative bleeding (mL) | 754.3 ± 600.9 (200–3200) | 386.0 ± 251.8(200–1800) | 0.001 |
| Operative time (min) | 310.0 ± 82.7 (100–470) | 224.3 ± 77.3(100–400) | < 0.001 |
| R0 | 36 (76.6%) | 127 (87.6%) | 0.068 |
| Mortality (number of patients) | 3 (6.4%) | 3 (2.1%) | 0.141 |
| Morbidity (need invasive treatment) | 16 (34.0%) | 18 (12.4%) | 0.001 |
Note that adjacent organs include the pancreas, duodenum, stomach, and/or colon other than the liver and extrahepatic bile duct.
Figure 3Actuarial survival curve of 192 gallbladder cancer patients following surgical resection with curative intent.
Figure 4Actuarial survival curve according to preoperative jaundice (with vs. without jaundice: p < 0.001).
Univariate analysis of 14 variables related to survival of GBC patients who underwent surgical resection with curative intent (n = 192)
| Variable | Cutoff level | Number | Survival rates (%) | p-value | |
|---|---|---|---|---|---|
| 3 year | 5 year | ||||
| Age (year) | 0.012 | ||||
| < 60 | 107 | 43.2 | 39.0 | ||
| ≥ 60 | 85 | 25.5 | 15.3 | ||
| Sex | 0.805 | ||||
| Male | 66 | 34.9 | 24.4 | ||
| Female | 126 | 35.9 | 29.7 | ||
| Jaundice | < 0.001 | ||||
| Present | 47 | 6.0 | 6.0 | ||
| Absent | 145 | 42.9 | 36.0 | ||
| Associated gallstone | 0.577 | ||||
| Present | 106 | 35.3 | 25.8 | ||
| Absent | 86 | 35.3 | 30.9 | ||
| Curability | < 0.001 | ||||
| Curative | 163 | 40.4 | 32.1 | ||
| Non-curative | 29 | 7.9 | 7.9 | ||
| Tumor location | < 0.001 | ||||
| Gallbladder neck | 54 | 12.7 | 9.5 | ||
| Gallbladder body/fundus | 138 | 44.0 | 35.9 | ||
| pT (TNM) | < 0.001 | ||||
| pT1 and 2 | 95 | 57.4 | 49.5 | ||
| pT3 and 4 | 97 | 12.8 | 6.4 | ||
| Lymph node metastasis | < 0.001 | ||||
| Negative | 90 | 55.1 | 43.5 | ||
| Positive | 102 | 17.5 | 14.6 | ||
| Histologic differentiation | 0.154 | ||||
| Well/Moderate | 161 | 36.0 | 30.8 | ||
| Poor | 31 | 32.1 | 11.5 | ||
| Hepatic invasion | < 0.001 | ||||
| Present | 90 | 14.2 | 6.7 | ||
| Absent | 102 | 53.1 | 45.9 | ||
| CRAO | < 0.001 | ||||
| Present | 15 | 0.0 | 0.0 | ||
| Absent | 177 | 36.0 | 28.7 | ||
| Combined portal vein/hepatic artery resection | 0.041 | ||||
| Present | 5 | 0.0 | 0.0 | ||
| Absent | 187 | 37.8 | 30.1 | ||
| Intraoperative blood infusion | 0.011 | ||||
| Present | 44 | 16.6 | 5.5 | ||
| Absent | 148 | 41.1 | 35.2 | ||
| Adjuvant therapy | 0.782 | ||||
| Yes | 28 | 31.6 | 13.2 | ||
| No | 164 | 35.8 | 30.4 | ||
| Overall | 192 | 35.3 | 28.1 | ||
Results of multivariate analysis
| Variable | Regression coefficient | Standard error | p-value | Relative risk | 95% CI |
|---|---|---|---|---|---|
| Age | 0.287 | 0.189 | 0.129 | 1.332 | 0.920–1.928 |
| Jaundice | -0.289 | 0.277 | 0.295 | 0.749 | 0.435–1.287 |
| Curability | 0.166 | 0.260 | 0.523 | 1.181 | 0.709–1.965 |
| Tumor location | -0.691 | 0.231 | 0.003 | 0.501 | 0.318–0.788 |
| pT | 0.292 | 0.416 | 0.482 | 1.339 | 0.593-3.026 |
| Lymph node metastasis | -0.453 | 0.225 | 0.044 | 0.636 | 0.409–0.987 |
| Hepatic invasion | -0.641 | 0.384 | 0.095 | 0.527 | 0.248–1.119 |
| CRAO | -0.013 | 0.359 | 0.972 | 0.987 | 0.489–1.994 |
| Combined portal vein/hepatic artery resection | -0.741 | 0.563 | 0.188 | 0.477 | 0.158–1.437 |
| Intraoperative blood infusion | -0.347 | 0.246 | 0.159 | 0.707 | 0.436–1.145 |
Univariate and multivariate analyses of 14 variables related to survival of GBC patients with preoperative jaundice (n = 47)
| Variable | Cutoff level | Number | Survival rates (%) | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|---|
| 1 year | 3 year | p-value | RR (95% CI) | P | |||
| Age (year) | 0.980 | ||||||
| < 60 | 26 | 42.1 | 8.0 | ||||
| ≥ 60 | 221 | 25.5 | 15.3 | ||||
| Sex | 0.477 | ||||||
| Male | 21 | 36.6 | 24.4 | ||||
| Female | 26 | 39.6 | 29.7 | ||||
| Preoperative biliary drainage | 0.968 | ||||||
| Present | 19 | 37.9 | 6.3 | ||||
| Absent | 28 | 38.5 | 8.7 | ||||
| Associated gallstone | 0.341 | ||||||
| Present | 26 | 53.8 | 11.5 | ||||
| Absent | 21 | 54.5 | 0.0 | ||||
| Curability | 0.004 | 2.845 (1.314–6.158) | 0.008 | ||||
| Curative | 36 | 47.0 | 7.2 | ||||
| Non-curative | 11 | 9.1 | 0.0 | ||||
| Tumor location | 0.699 | ||||||
| Gallbladder neck | 28 | 42.5 | 8.5 | ||||
| Gallbladder body/fundus | 19 | 30.7 | 0.0 | ||||
| pT (TNM) | 0.170 | ||||||
| pT1 and 2 | 16 | 42.2 | 12.7 | ||||
| pT3 and 4 | 31 | 35.2 | 4.4 | ||||
| Lymph node metastasis | 0.328 | ||||||
| Negative | 17 | 47.1 | 7.8 | ||||
| Positive | 30 | 32.2 | 10.1 | ||||
| Histologic differentiation | 0.432 | ||||||
| Well/Moderate | 43 | 38.8 | 6.0 | ||||
| Poor | 4 | 25.0 | 0.0 | ||||
| Hepatic invasion | 0.728 | ||||||
| Present | 26 | 30.5 | 6.1 | ||||
| Absent | 21 | 46.2 | 8.8 | ||||
| CRAO | 0.728 | ||||||
| Present | 11 | 43.6 | 0.0 | ||||
| Absent | 36 | 35.9 | 7.2 | ||||
| Intraoperative blood infusion | 0.893 | ||||||
| Present | 25 | 34.5 | 12.9 | ||||
| Absent | 22 | 41.5 | 0.0 | ||||
| Adjuvant therapy | 0.179 | ||||||
| Yes | 7 | 51.4 | 25.7 | ||||
| No | 40 | 35.6 | 4.9 | ||||
| Overall | 47 | 37.8 | 6.0 | ||||
Figure 5Actuarial survival curve according to tumor location (gallbladder neck vs. gallbladder body/fundus: p < 0.001).
Univariate and multivariate analyses for hospital mortality in GBC patients who underwent surgical resection with curative intent (n = 192)
| Variables | No. of patients | Morbidity | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
| p-value | RR (95% CI) | p-value | ||||
| Gender | 0.128 | |||||
| Female | 126 | 18 (14.3%) | ||||
| Male | 66 | 16 (24.2%) | ||||
| Age | 0.505 | |||||
| < 60 years | 107 | 17 (15.9%) | ||||
| ≥ 60 years | 85 | 17 (20.0%) | ||||
| Preoperative jaundice | 0.034 | 0.387 (0.164–0.916) | 0.031 | |||
| Present | 47 | 16 (34.0%) | ||||
| Absent | 145 | 18 (12.4%) | ||||
| Major hepatectomy | 0.183 | |||||
| Yes | 8 | 4 (50.0%) | ||||
| No | 184 | 30 (16.3%) | ||||
| Extrahepatic bile duct resection | 0.717 | |||||
| With | 56 | 17 (30.4%) | ||||
| Without | 136 | 17 (12.5%) | ||||
| Combined resection of adjacent organs (CRAO) | 0.168 | |||||
| With | 15 | 7 (46.7%) | ||||
| Without | 177 | 27 (15.3%) | ||||
| Combined portal vein/hepatic artery resection | 0.802 | |||||
| With | 5 | 1 (20.0%) | ||||
| Without | 187 | 33 (17.6%) | ||||
| Operative time 0.280 | ||||||
| < 240 min | 87 | 9 (10.3%) | ||||
| ≥ 240 min | 105 | 25 (23.8%) | ||||
| Intraoperative blood infusion 0.056 | 0.420 (0.175-1.007) | 0.052 | ||||
| With | 44 | |||||
| Without | 148 | |||||
Adjacent organs include the pancreas, duodenum, stomach, and/or colon other than the liver and bile duct.
Univariate analyses for hospital mortality in GBC patients with preoperative jaundice (n = 47)
| Variable | No. of patients | Morbidity | Univariate | |
|---|---|---|---|---|
| p-value | ||||
| Gender | 0.927 | |||
| Female | 26 | 14 (36.8%) | ||
| Male | 21 | 2 (22.2%) | ||
| Age | 0.927 | |||
| < 57 years | 26 | 6 (31.6%) | ||
| ≥ 57 years | 21 | 10 (35.7%) | ||
| pEBI | 0.405 | |||
| Yes | 38 | 2 (50.0%) | ||
| No | 9 | 14 (32.6%) | ||
| Preoperative biliary drainage | 0.769 | |||
| Yes | 19 | 15 (34.1%) | ||
| No | 28 | 1 (33.3%) | ||
| Major hepatectomy | 0.481 | |||
| Yes | 4 | 5 (45.5%) | ||
| No | 43 | 11 (30.6%) | ||
| Extrahepatic bile duct resection | 0.979 | |||
| With | 44 | 1 (50.0%) | ||
| Without | 3 | 15 (33.3%) | ||
| CRAO | 0.361 | |||
| With | 11 | 8 (44.4%) | ||
| Without | 36 | 8 (27.6%) | ||
| Combined portal vein/hepatic artery resection | 0.626 | |||
| With | 2 | |||
| Without | 45 | |||
| Operative time | 0.236 | |||
| < 300 min | 18 | 8 (32.0%) | ||
| ≥ 300 min | 29 | 8 (36.4%) | ||
| Intraoperative blood infusion | 0.753 | |||
| With | 25 | 8 (32.0%) | ||
| Without | 22 | 8 (36.4%) | ||
Note that adjacent organs include the pancreas, duodenum, stomach, and/or colon other than the liver and bile duct.
Compared analyses for jaundiced patients with and without PBD (n = 47)
| Variables | With PBD,n = 19 | Without PBD, n = 28 | p-value | |
|---|---|---|---|---|
| Male gender | 6 | 15 | 0.141 | |
| Mean age (range) | 55.2 ± 11.1 | 59.0 ± 10.9 | 0.247 | |
| Postoperative hospital stay | 18.8 ± 9.1 | 20.4 ± 15.6 | 0.689 | |
| Bilirubin level at presentation | 234.0 ± 120.5 | 194.4 ± 125.7 | 0.287 | |
| Intra-operative bleeding (mL) | 800.0 ± 761.4 | 723.2 ± 475.6 | 0.672 | |
| Operative time (min) | 328.9 ± 77.7 | 297.1 ± 84.8 | 0.199 | |
| R0 | 15 (78.9) | 21 (75.0) | 0.795 | |
| Mortality (number of patients) | 1 (5.3%) | 2 (7.1%) | 0.854 | |
| Morbidity (need invasive treatment) | 6 (31.6%) | 10 (35.7%) | 0.755 | |
| Intra-abdominal abscesses | 4 (21.1%) | 5 (17.9%) | 0.787 | |
| Survival | 0.968 | |||
| One-year survival | 37.9% | 38.5% | ||
| Three-year survival | 6.3% | 8.7% | ||